Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK closes sale of thrombosis brands to Aspen

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline has completed the £700m sale of two thrombosis brands to South Africa's largest listed pharma company, Aspen. The previously announced deal (scripintelligence.com, 30 September 2013) closed following regulatory approval of the transaction. The majority of commercial operations will formally transfer to Aspen on 1 January 2014 with the remainder, as well as the Notre-Dame de Bondeville manufacturing site, transferring in mid-2014.The brands in question are Arixtra (fondaparinux) and Fraxiparine (nadroparin), which booked combined sales of £177m in the first half of 2013.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC023953

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel